WFDF Procedure - Review Regarding Adverse Analytical Findings

as of 28 May 2020

1. Review Regarding Adverse Analytical Findings

Upon receipt of an Adverse Analytical Finding (AAF), WFDF if being responsible for results management, shall conduct a review to determine whether:

(a) an applicable TUE has been granted or will be granted as provided in the International Standard for Therapeutic Use Exemptions or
(b) there is any apparent departure from the International Standard for Testing and Investigations or International Standard for Laboratories that caused the Adverse Analytical Finding.

Where a retroactive TUE is granted pursuant to Article 4.3(d) of the ISTUE, WFDF will seek WADA’s prior approval.

Timeliness: In the interest of fair, effective sport justice, any asserted ADRV should be prosecuted in a timely manner. Irrespective of the type of ADRV involved, WFDF will be able to conclude Results Management and the hearing process within a maximum of 6 months of the date of commission or of discovery of the Anti-Doping Rule Violation (ADRV).

2. Notification After Review Regarding Adverse Analytical Findings

If the review of an Adverse Analytical Finding under Article 7.2 does not reveal an applicable TUE or entitlement to a TUE as provides in the International Standard for Therapeutic Use Exemptions, or departure that caused the Adverse Analytical Finding, WFDF shall promptly notify the Athlete in the manner set out in Articles 14.1.1. and 14.1.3 and its own rules, of

(a) the Adverse Analytical Finding;
(b) the Anti-Doping rule violated; and
(c) the Athlete’s right to promptly request the analysis of the B Sample or, failing such request, that B Sample analysis may be deemed waived;
(d) the scheduled date, time and place for the B Sample analysis if the Athlete or IFI chooses to request an analysis of the B Sample;
(e) the opportunity for the Athlete and/or Athlete’s representative to attend the B Sample opening and analysis within the time period specified in the International Standard for Laboratories if such analysis is requested; and
(f) the Athlete’s right to request copies of the A and B Sample laboratory documentation package which includes information as required by the International Standard Laboratories.

If WFDF decides not to bring forward the Adverse Analytical Finding as an Anti-Doping Rule Violation (ADRV), it shall notify the Athlete as described in Article 14.1.2.

In all cases where an Athlete has been notified of ADRV that does not result in a mandatory Provisional Suspension under Article 7.9.1, the Athlete shall be offered the opportunity to accept a Provisional Suspension pending the resolution of the matter.

3. Further principles of review

The review principles are governed by the WADA Results Management, Hearings and Decisions Guidelines in its current version, particularly for an Atypical Finding (ATF) where the procedure will follow Annex C to the ISTUE.

submitted by Volker Bernardi, WFDF Executive Director